About CD5 antigen-like
CD5 antigen-like (CD5L) is a protein
from Homo sapiens identified by UniProt accession
O43866, 347 residues long.
MolForge cross-references it against 0 known binders and
219 disease associations.
Target properties
| Protein name | CD5 antigen-like |
|---|
| UniProt accession | O43866 |
|---|
| Gene | CD5L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 347 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (219)
Diseases linked to this target (Open Targets).
- DNA methylation · score 0.31
- blood protein measurement · score 0.21
- hepatocellular carcinoma · score 0.12
- neoplasm · score 0.09
- acute respiratory distress syndrome · score 0.07
- common variable immunodeficiency · score 0.06
- experimental autoimmune encephalomyelitis · score 0.06
- Immunodeficiency due to a late component of complements deficiency · score 0.06
- isolated agammaglobulinemia · score 0.06
- X-linked severe congenital neutropenia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43866-F1 | alphafold | PREDICTED | 85.86 | — |
Amino-acid sequence (347 residues)
MALLFSLILA ICTRPGFLAS PSGVRLVGGL HRCEGRVEVE QKGQWGTVCD DGWDIKDVAV LCRELGCGAA SGTPSGILYE PPAEKEQKVL IQSVSCTGTE DTLAQCEQEE VYDCSHDEDA GASCENPESS FSPVPEGVRL ADGPGHCKGR VEVKHQNQWY TVCQTGWSLR AAKVVCRQLG CGRAVLTQKR CNKHAYGRKP IWLSQMSCSG REATLQDCPS GPWGKNTCNH DEDTWVECED PFDLRLVGGD NLCSGRLEVL HKGVWGSVCD DNWGEKEDQV VCKQLGCGKS LSPSFRDRKC YGPGVGRIWL DNVRCSGEEQ SLEQCQHRFW GFHDCTHQED VAVICSG
Explore CD5 antigen-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets